OPTH ▲ +2.8% - Optimi Health Corp. $OPTH - Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply Optimi Health rose 2.8% after announcing the completion of psilocybin production for a Health Canada-approved Phase 2 clinical trial in major depressive disorder and commercial supply for treatment-resistant depression. The milestone demonstrates progress toward potential clinical validation and commercial readiness in the emerging psilocybin therapeutics market. 23-SEP-2026 09:00 AM ET